中国医药
(600056)
| 流通市值：162.99亿 | | | 总市值：163.05亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 29,796,767,468.5 | 21,624,971,226.54 | 12,530,663,199.18 | 37,592,649,532.91 |
| 营业收入 | 29,796,767,468.5 | 21,624,971,226.54 | 12,530,663,199.18 | 37,592,649,532.91 |
| 二、营业总成本 | 28,684,951,933.56 | 20,720,802,502.03 | 12,093,668,632.79 | 36,137,940,473.13 |
| 营业成本 | 26,495,902,600.95 | 19,221,118,821.91 | 11,297,491,990.29 | 32,845,785,875.24 |
| 税金及附加 | 95,639,472.13 | 67,534,029.02 | 32,380,793.2 | 115,297,232.33 |
| 销售费用 | 1,210,013,723.99 | 868,188,913.16 | 463,351,369.54 | 1,950,511,550.6 |
| 管理费用 | 742,690,490.07 | 486,441,145.91 | 230,026,259.55 | 1,010,700,146.35 |
| 研发费用 | 73,476,169.58 | 53,670,871.23 | 27,176,715.85 | 77,328,959.85 |
| 财务费用 | 67,229,476.84 | 23,848,720.8 | 43,241,504.36 | 138,316,708.76 |
| 其中:利息费用 | 115,183,765.19 | 74,208,125.55 | 42,736,450.78 | 217,580,855.62 |
| 其中:利息收入 | 42,295,218.11 | 22,955,065.85 | 13,293,704.46 | 35,225,018.35 |
| 加:公允价值变动收益 | 334,265.95 | 32,725.27 | 827,810.11 | 1,922,290.19 |
| 加:投资收益 | 27,818,368.53 | 31,407,648.52 | 15,302,950.13 | 51,000,950.95 |
| 资产处置收益 | 2,665,861.35 | 2,667,460.71 | 2,832,053.23 | 16,348,712.81 |
| 资产减值损失(新) | 4,428,254.65 | -1,648,916.38 | -69,833.43 | -280,659,988.09 |
| 信用减值损失(新) | -85,886,115.51 | -90,279,979.18 | -54,319,761.62 | -90,322,028.02 |
| 其他收益 | 44,312,700.18 | 26,795,194.54 | 5,277,123.15 | 46,698,985.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,105,488,870.09 | 873,142,857.99 | 406,844,907.96 | 1,199,697,983.22 |
| 加:营业外收入 | 14,696,448.87 | 7,456,861.61 | 211,653.19 | 14,910,795 |
| 减:营业外支出 | 11,034,810.29 | 6,299,083.13 | 446,211.89 | 18,481,737.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,109,150,508.67 | 874,300,636.47 | 406,610,349.26 | 1,196,127,041.17 |
| 减:所得税费用 | 325,487,725.89 | 197,547,306.33 | 86,028,006.93 | 308,158,842.73 |
| 六、净利润 | 783,662,782.78 | 676,753,330.14 | 320,582,342.33 | 887,968,198.44 |
| 持续经营净利润 | 783,662,782.78 | 676,753,330.14 | 320,582,342.33 | 887,968,198.44 |
| 归属于母公司股东的净利润 | 594,110,580.95 | 543,547,678.43 | 268,770,140.93 | 735,705,209.39 |
| 少数股东损益 | 189,552,201.83 | 133,205,651.71 | 51,812,201.4 | 152,262,989.05 |
| (一)基本每股收益 | 0.4 | 0.36 | 0.18 | 0.49 |
| (二)稀释每股收益 | 0.4 | 0.36 | 0.18 | 0.49 |
| 八、其他综合收益 | 706,621.64 | 1,619,270.62 | 225,522.18 | 8,059,188.2 |
| 归属于母公司股东的其他综合收益 | 706,621.64 | 1,619,270.62 | 225,522.18 | 8,499,394.42 |
| 九、综合收益总额 | 784,369,404.42 | 678,372,600.76 | 320,807,864.51 | 896,027,386.64 |
| 归属于母公司股东的综合收益总额 | 594,817,202.59 | 545,166,949.05 | 268,995,663.11 | 744,204,603.81 |
| 归属于少数股东的综合收益总额 | 189,552,201.83 | 133,205,651.71 | 51,812,201.4 | 151,822,782.83 |
| 公告日期 | 2023-10-28 | 2023-08-25 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |